The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1324
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved use of tadalafil (Adcirca – Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH). Tadalafil is also marketed as Cialis for treatment of erectile dysfunction.1

DRUGS FOR PAH — Current management of PAH usually includes warfarin (Coumadin, and others) and furosemide (Lasix, and others). Oral drugs approved for PAH include sildenafil (Revatio), a phosphodiesterase type 5 (PDE5) inhibitor, bosentan (Tracleer), a nonselective endothelin receptor antagonist, and ambrisentan (Letairis), a selective endothelin type A receptor antagonist.2 Patients with more advanced disease can be treated with a systemic prostacyclin such as iloprost (Ventavis) or treprostinil (Tyvaso) given as multiple daily inhalations, or epoprostenol (Flolan) or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
Article code: 1324b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian